Masimo Corp (NASDAQ: MASI)

Sector: Healthcare Industry: Medical Devices CIK: 0000937556
Market Cap 9.50 Bn
P/E 22.45
P/S 6.22
Div. Yield 0.00
ROIC (Qtr) 0.18
Total Debt (Qtr) 518.00 Mn
Revenue Growth (1y) (Qtr) 11.97
Add ratio to table...

About

Masimo Corp, known by its ticker symbol MASI, is a global technology company operating in the healthcare and non-healthcare sectors. The company's main business activities revolve around developing, manufacturing, and marketing noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices, and consumer health products in the healthcare segment. In the non-healthcare segment, Masimo focuses on premium home sound integration technologies and accessories, as well as licensing high-performance...

Read more

Investment thesis

Bull case

  • Masimo’s third‑quarter operating margin of 27.1% represents a 450 basis‑point lift from the prior year, driven largely by 590 basis‑point operational efficiency gains that outpace the 140‑basis‑point tariff drag. The company’s management highlighted that, excluding tariffs, operating margin would be 28.5%, comfortably above the industry average for non‑invasive monitoring firms. This margin expansion is underpinned by a scalable cost‑structure that has already absorbed the impact of new U.S. tariffs, suggesting the ability to maintain or even improve profitability as the company ramps up contract execution. With a robust free‑cash‑flow generation of $57 million in the quarter and an aggressive capital deployment plan that has already repurchased 2.4 million shares, Masimo’s balance sheet remains healthy and well‑positioned to fund future growth initiatives without external financing.
  • The expanded partnership with Philips, announced early in the fiscal year, has opened a high‑penetration channel into one of the largest global hospital ecosystems. Management noted that Masimo’s market share within the Philips installed base remains “disproportionately low” relative to its overall 50 % market share, indicating significant upside potential. By embedding Masimo’s advanced sensors and the SET® technology directly into Philips monitors, the company can capture incremental revenue across a spectrum of monitoring categories—pulse oximetry, capnography, and brain activity monitoring—without the need for separate sales cycles. The partnership also creates a defensible moat, as Philips’ distribution network and contractual relationships with hospitals reduce acquisition costs and accelerate deployment timelines. Over the next five years, this channel is projected to deliver a compound annual growth rate that exceeds the company’s 8 %–10 % guidance, providing a credible tail‑wind for both top‑line and margin expansion.
  • Masimo’s next‑generation AI‑enabled sensor aimed at detecting opioid‑induced respiratory depression (OIRD) aligns with the 2026 CMS reporting requirements for hospitals. The technology has already secured FDA clearance for the algorithm, and the company plans to integrate it into its upcoming smart sensor line by the end of next year. By positioning itself as a first‑mover in this niche, Masimo can capture a new revenue stream from both hospital contracts and potentially from payers seeking to demonstrate compliance with quality metrics. The regulatory pathway is clear, and the existing SET® platform provides a proven foundation for rapid scaling, suggesting that the transition from proof‑of‑concept to commercial launch could be executed with minimal risk. This product line not only diversifies the company’s portfolio but also strengthens its competitive edge in the evolving value‑based care landscape.
  • The company’s wearable initiatives, notably the Radius VSM and Radius PPG, are progressing from pilot to planned full market launch. These wrist‑mounted, non‑invasive monitors leverage Masimo’s SET® accuracy advantage while addressing a growing demand for remote patient monitoring. By tapping into the burgeoning telehealth market, Masimo can capture a new customer segment—home‑care patients and outpatient settings—that has historically been underserved by its traditional inpatient focus. Early pilots have demonstrated operational feasibility and cost‑effectiveness, and the company’s data analytics platform can aggregate patient information across both inpatient and outpatient environments, creating an additional revenue layer through subscription services. As the COVID‑19 pandemic accelerated the adoption of remote monitoring, the timing of this launch positions Masimo to benefit from a sustained shift toward home‑based care.
  • Masimo’s disciplined capital allocation—debt repayment and large share‑repurchase program—has already enhanced shareholder value and reduced leverage. By returning $350 million to shareholders and repaying $56 million of debt, the company improved its debt‑to‑EBITDA ratio and freed cash for strategic acquisitions. The management’s stated intent to use future proceeds from the Sound United divestiture for tuck‑in technology acquisitions indicates a focused approach to portfolio growth that can accelerate revenue diversification without diluting existing operations. This capital strategy not only protects margins but also positions Masimo to capitalize on opportunistic acquisitions in complementary areas such as biosensor data analytics or patient‑monitoring automation, thereby creating synergies that can generate above‑average returns on invested capital.
Read more

Bear case

  • Despite the headline margin gains, Masimo remains exposed to the volatility of U.S. tariffs, which added $5 million to cost of sales and erased 140 basis‑points of margin. The company’s guidance explicitly incorporates a $6 million revenue headwind from its shift to a distributor model in certain international markets, underscoring the sensitivity of revenue to policy and trade dynamics. If the U.S. government enacts additional tariffs on medical components, the incremental cost impact could erode the modest operating margin expansion and negate the benefits of the company’s cost‑efficiency initiatives. Moreover, the lack of a clear hedging strategy against tariff escalation presents an unquantified risk that could materialize into a negative operating leverage shift.
  • The transition to a distributor model in some overseas markets is a double‑edged sword. While management assures that profitability is neutral, the shift removes Masimo’s direct control over sales channels, pricing, and customer relationships in those regions. This could result in longer sales cycles, diminished brand visibility, and reduced ability to capture incremental margin on international shipments. Furthermore, the $6 million revenue headwind projected for the full year indicates a tangible shortfall that may not be fully offset by domestic contract growth, potentially compressing revenue growth and making the company vulnerable to macroeconomic downturns in high‑growth markets.
  • Masimo’s core product, the SET® pulse oximetry platform, faces intense competition from Medtronic and other entrants that have begun offering comparable low‑motion, low‑perfused sensors. The company’s high market share in pulse oximetry has not translated into a strong foothold within the Philips installed base, suggesting a limited competitive moat in the broader monitoring arena. As competitors invest in AI‑enabled monitoring and expand their product suites, Masimo’s reliance on a single technology cluster could expose the company to erosion of demand, especially if pricing pressures intensify in a saturated market. Additionally, the company’s reliance on a patented technology base that is under litigation with Apple introduces a strategic vulnerability that could disrupt supply chains and limit the scalability of new product lines.
  • The ongoing patent dispute with Apple remains a significant legal and financial risk. While a recent jury award favored Masimo, the litigation landscape is still unsettled, and future rulings could impose costly licensing fees or injunctions that restrict Masimo’s ability to commercialize its blood‑oxygen technology in smartwatches and other consumer devices. The legal costs associated with defending these patents are substantial and could erode earnings, while the uncertainty surrounding the outcome may deter potential partners who fear a sudden change in IP ownership or royalty obligations. This litigation risk is compounded by Masimo’s history of high‑profile IP battles, which can strain management’s focus and divert resources from core R&D initiatives.
  • The speculative acquisition by Danaher introduces an external threat that could alter Masimo’s strategic trajectory. Danaher’s intent to acquire Masimo at a 38 % premium suggests a valuation that may overstate the company’s intrinsic worth given its current cash flows and growth prospects. Should the deal materialize, shareholders could face dilution, a shift in corporate culture, and potential realignment of product priorities that may dilute Masimo’s focus on advanced monitoring. Moreover, the integration process could disrupt supply chains, delay product launches, and erode the company’s competitive advantage. Until the transaction is finalized, the possibility of a takeover adds an element of uncertainty that can weigh on the stock price and affect long‑term strategic planning.
Read more

Segments Breakdown of Revenue (2026)

Related and Nonrelated Parties Breakdown of Revenue (2026)

Peer comparison

Companies in the Medical Devices
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ABT Abbott Laboratories 177.36 Bn 27.31 4.00 12.93 Bn
2 SYK Stryker Corp 124.60 Bn 38.40 4.96 15.86 Bn
3 MDT Medtronic plc 109.93 Bn 23.82 3.10 28.07 Bn
4 BSX Boston Scientific Corp 93.15 Bn 31.94 4.64 11.44 Bn
5 EW Edwards Lifesciences Corp 46.49 Bn 43.68 7.66 0.60 Bn
6 PHG Koninklijke Philips Nv 29.40 Bn 25.00 1.46 9.41 Bn
7 DXCM Dexcom Inc 24.14 Bn 28.78 5.18 -
8 STE STERIS plc 21.56 Bn 30.26 3.70 1.90 Bn